CN115040591B

CN115040591B - Auxiliary antihypertensive composition and application thereof

Info

Publication number: CN115040591B
Application number: CN202210707723.XA
Authority: CN
Inventors: 汪玉芳; 贺瑞坤; 张旭光; 岳中宝; 胡明华
Original assignee: BY Health Co Ltd
Current assignee: BY Health Co Ltd
Priority date: 2022-06-21
Filing date: 2022-06-21
Publication date: 2023-11-07
Anticipated expiration: 2042-06-21
Also published as: CN115040591A

Abstract

The application discloses an auxiliary blood pressure reducing composition and application thereof, and belongs to the field of medicines, health-care foods or foods. The composition comprises the following components in parts by weight: 3-5 parts of cinnamon extract, 10-20 parts of eucommia bark extract, 10-20 parts of pagodatree flower extract, 5-10 parts of grape seed extract and 25-30 parts of cocoa extract. The composition can regulate the levels of Ang II, ET-1 and NO in serum through the compound effect of the components, and the components have synergistic effect, so that the composition has excellent blood pressure reducing function.

Description

Auxiliary antihypertensive composition and application thereof

Technical Field

The application belongs to the field of medicines, health-care foods or foods, and relates to an auxiliary blood pressure reducing composition and application thereof.

Background

With age, the prevalence of hypertension and the degree of vascular aging increase. Hypertension and vascular aging are dangerous elements in the development of atherosclerosis, which leads to increased cardiovascular disease and mortality. Hypertension is a major risk factor for cardiovascular diseases, is a common disease with higher worldwide morbidity, seriously endangers human health, and is mainly characterized by that the arterial pressure of the systemic circulation exceeds a normal value. The existing clinically applied medicines for preventing and treating hypertension are many, and although the medicines can effectively reduce blood pressure, the side effects are large, and the fluctuation in the blood pressure reduction process is large. Therefore, the screening and research of the functional food factors with the antihypertensive effect is of great significance.

In the hypertension detection index, endothelin (ET) and Nitric Oxide (NO) are a pair of vasoactive substances with antagonistic efficacy, vascular endothelial cells secrete ET and NO simultaneously according to a certain proportion, normal vascular tension is maintained by dynamic balance between the two substances, and the vascular endothelial cells and the NO are the most main factors for regulating vascular tension and maintaining stable blood pressure, and if the vascular tension and the NO are unbalanced, primary hypertension can be caused. ACE is a dependent carboxydipeptidase, is a membrane-integrated single-chain glycoprotein, and can convert low-activity decapeptide angiotensin I (ngiotensin I, ang I) into Ang II under the action of ACE, and AT1R in Ang II can play roles in vasoconstriction, vascular smooth muscle proliferation and function and water salt metabolism regulation.

Chinese patent application 201910210079.3 discloses a composition with blood pressure reducing effect and application thereof, wherein the composition comprises the following components in parts by weight: 10-50 parts of semen cassiae, 10-30 parts of medlar, 10-50 parts of gardenia, 10-50 parts of poria cocos, 5-10 parts of ginger, 10-50 parts of radix puerariae, 10-50 parts of dandelion, 10-50 parts of Chinese yam and 10-50 parts of chicory. The composition has the effects of treating hypertension, repairing blood vessels, protecting livers, cleaning blood vessels, intestines and stomach, kidneys and wastes in livers, and is beneficial to the treatment of patients with hypertension. However, the above disclosed composition has not been studied on the mechanism of blood pressure reduction, nor has the effect of blood pressure reduction been quantified.

Chinese patent application 201911332420.9 discloses a composition with blood pressure reducing effect, which comprises the following raw material components in parts by weight: 5-15 parts of soybean peptide, 1-3 parts of raspberry extract, 1-3 parts of rhodiola rosea extract, 1-3 parts of rhizoma polygonati extract, 1-3 parts of grape seed extract, 1-3 parts of green tea extract, 1-3 parts of moringa leaf extract, 0.5-2 parts of theanine, 0.5-2 parts of astaxanthin, 0.5-2 parts of lycopene, 0.5-2 parts of resveratrol, 0.5-2 parts of curcumin, 0.1-1 part of EPA, 0.1-1 part of DHA, 0.1-1 part of cyanidin and 0.1-1 part of delphinidin; the blood pressure reducing agent not only can play a role in synergy in reducing blood pressure, effectively reduces the blood pressure of a hypertensive patient, keeps the blood pressure of the hypertensive patient in a stable state for a long time, but also can play a role in synergy in reducing cholesterol and blood fat and improving antioxidant function, alleviate and improve vascular function, improve organism immunity, remove substances deposited in blood vessels and blocking blood vessels, and relieve and improve occurrence and development of hypertension. However, the above disclosed composition has a large prescription and a complex raw material composition.

Therefore, there is a need to explore a composition which has simple raw material components, is low in cost and can effectively reduce blood pressure.

Disclosure of Invention

Aiming at the problems existing in the prior art, the application provides an auxiliary antihypertensive composition with wide component sources, low cost and good treatment effect and application thereof.

In order to achieve the above purpose, the technical scheme adopted by the application is as follows:

first, a composition is provided, which comprises cinnamon extract, eucommia bark extract, pagodatree flower extract, grape seed extract, cocoa extract.

Further, the composition comprises the following components in parts by weight: 3-5 parts of cinnamon extract, 10-20 parts of eucommia bark extract, 10-20 parts of pagodatree flower extract, 5-10 parts of grape seed extract and 25-30 parts of cocoa extract.

Further, the weight ratio of the cinnamon extract to the eucommia bark extract to the sophora flower extract is 3-5:10-20:10-20.

Preferably, the weight ratio of the cinnamon extract to the eucommia bark extract to the sophora flower extract is 4-5:12-18:12-18.

Further, the weight ratio of the grape seed extract to the cocoa extract is 5-10:25-30.

Preferably, the weight ratio of grape seed extract to cocoa extract is 6-10:27-28.

Furthermore, the preparation method of the composition comprises the step of simply mixing all raw materials according to the weight ratio.

Secondly, the application of the composition in preparing products with the function of reducing blood pressure is provided.

Further, the blood pressure reduction means reducing Ang II in serum, and/or reducing ET-1 in serum, and/or increasing NO in serum, wherein Ang II is angiotensin II, ET-1 is endothelin-1, and NO is nitric oxide.

Further, the blood pressure reducing mechanism is to regulate vascular endothelial function by regulating generation and release of AngII, ET-1 and NO, so as to relax blood vessels to reduce blood pressure.

Further, the product is any one of medicines, dietary supplements and health-care foods.

Further, the product is in any one of a tablet, a capsule and a powder.

Further, the product can be added with auxiliary materials besides five components of cinnamon extract, eucommia bark extract, pagodatree flower extract, grape seed extract and cocoa extract, wherein the auxiliary materials comprise one or more of filling agent, disintegrating agent, adhesive and wetting agent.

Further, the filler comprises one or more of magnesium stearate, maltodextrin, starch, corn starch, pregelatinized starch, dextrin and microcrystalline cellulose.

Further, the disintegrating agent comprises one or more of croscarmellose sodium, crospovidone, sodium carboxymethyl starch and low-substituted hydroxypropyl cellulose.

Further, the adhesive comprises one or more of hypromellose, povidone, starch slurry, dextrin, sugar powder and syrup, sodium carboxymethyl cellulose, hydroxypropyl cellulose and microcrystalline cellulose.

Further, the wetting agent comprises one or more of silicon dioxide magnesium stearate, polyethylene glycol and sodium dodecyl sulfate.

The components of the composition provided by the application are as follows: cinnamaldehyde as an effective component of cinnamon has the effect of dilating blood vessels; the vasodilation effect of pinoresinol diglucoside and quercetin in eucommia ulmoides and sophora flower extracts has endothelial dependence, mainly by promoting the release of NO from endothelial cells to dilate blood vessels, while at high concentrations it is mainly by inhibiting Ca from vascular smooth muscle cells ²⁺ Channels and other ways to dilate blood vessels; grape seed extract can antagonize the action of histamine or prostaglandin for contracting artery, inhibit the activity of Angiotensin Converting Enzyme (ACE), and thereby reduce and maintain normal blood pressure; the cocoa extract can dilate blood vessels by increasing NO and inhibiting ACE; the folium Ginkgo extract has effects of dilating blood vessel, improving peripheral blood circulation, and reducing serum cholesterol; sang Sheneng inhibits the activity of angiotensin converting enzyme and promotes blood pressure drop.

Compared with the prior art, the application has the following beneficial effects:

(1) According to the auxiliary antihypertensive composition, the levels of Ang II, ET-1 and NO in serum can be regulated through the compounding effect among the components, and the components have synergistic effects, so that the auxiliary antihypertensive composition has an excellent antihypertensive function;

(2) The composition has the advantages of wide sources of raw materials, simple preparation method and low production cost.

Detailed Description

It is to be noted that the raw materials used in the present application are all common commercial products, and the sources thereof are not particularly limited.

The following reagents and instrument sources are exemplary illustrations:

cinnamon extract, eucommia bark extract, pagodatree flower extract, offered by the Guangdong Qingyun mountain pharmaceutical company limited; grape seed extract is provided by Ningbo traditional Chinese medicine pharmaceutical Co., ltd; cocoa extracts are provided by nanographic corporation; ginkgo biloba leaf extract, mulberry leaf extract is available from Guangdong Qingyun mountain pharmaceutical company. Captopril manufacturer: changzhou pharmaceutical factories, inc.; 0.5% cmc-Na (sodium carboxymethyl cellulose) supplied by the Tianjin metallocene chemical reagent plant; BP-2010A intelligent noninvasive sphygmomanometer manufacturer: beijing Soft-lone Biotechnology Co.

Preparation of the compositions of examples 1-4, comparative examples 1-6: the raw materials are uniformly mixed according to the weight ratio.

Examples 1 to 4, comparative examples 1 to 6

The formulations of example 14, comparative examples 1-6 are shown in Table 1:

TABLE 1

Experimental example

Test animals: 10 Wistar-Kyoto rats (WKY) and 120 male Spontaneous Hypertension Rats (SHR), after 7 days of quarantine period, were subjected to non-invasive rat tail blood pressure and heart rate tests (see tables 2 and 3) on day 0 using a BP-2010A intelligent non-invasive sphygmomanometer, 10 WKY rats were divided into normal groups, 120 SHR rats were randomly grouped by blood pressure, respectively, model group, example 1 group, example 2 group, example 3 group, example 4 group, comparative example 1 group, comparative example 2 group, comparative example 3 group, comparative example 4 group, comparative example 5 group, comparative example 6 group, positive drug captopril group, 10 each. The normal and model groups were given 10mL/kg of 0.5% CMC-Na, and each treatment group was given 10mL/kg of the corresponding sample. The tail artery systolic pressure and heart rate tests of 7d, 14d, 21d, 30d before and after administration are shown in tables 2 and 3.

And (3) data processing: blood pressure measurement data are metering data and can be analyzed by t test. The self-comparison data can adopt paired t-test, the two groups of average comparison adopts grouped t-test, the latter needs to carry out variance alignment test, proper variable conversion is carried out on data with non-normal distribution or uneven variance, and t-test is carried out on the converted data after normal variance alignment is satisfied; if the conversion data still cannot meet the normal variance alignment requirement, t-test or rank sum test is used instead; however, data with too large a coefficient of variation (e.g., CV > 50%) is subjected to rank sum test.

And (3) result judgment: the blood pressure of the animals in the experimental group is obviously lower than that of the animals in the model control group, the difference is remarkable, the heart rate of the animals in the experimental group and the blood pressure and heart rate of normal animals are not influenced, and the functional animal experiment result which is helpful for maintaining the healthy level of the blood pressure can be judged to be positive.

Results

TABLE 2 influence of sample on rat systolic blood pressure (X.+ -. SD)

Note that: comparison to model group,: p <0.05,: p <0.01.

As shown in table 2, 0-30d, model animals had significantly elevated systolic blood pressure (P < 0.01) compared to normal. Animals in the 7d, 14d positive group had significantly reduced systolic blood pressure (P < 0.01) after administration of the test sample compared to the model group; 21d, 30d animals from examples 1-4 and positive groups had significantly reduced systolic blood pressure (P < 0.01).

Table 3 heart rate variability (n=10, times/min) (x±sd) for each group of rats during the auxiliary hypotensive function test

Note that: comparison to model group,: p <0.05,: p <0.01.

As shown in table 3, in 0-30d, there was no statistical difference in heart rate (P > 0.05) in the model group rats compared to the normal group; compared with the model group, the heart rate of rats in each test sample group and the positive group has no statistical difference (P > 0.05).

TABLE 4 influence of sample on serum Ang II, NO, ET-1 levels in SHR rats (X.+ -. SD)

Note that: comparison to model group,: p <0.05,: p <0.01.

Table 4 shows changes in serum Ang II, NO, ET-1 levels of SHR rats after the end of the test period for auxiliary hypotension function. From Table 4, it can be seen that the serum levels of Ang II and endothelin (ET-1) were significantly increased (P <0.05 or P < 0.01) and the levels of NO were significantly decreased (P < 0.05) in the rats of the model group, as compared with the normal group, after 30d administration of the test sample. Compared to the model group, the Ang II levels in the serum of the rats of examples 1-4 were significantly reduced (P <0.05 or P < 0.01), the NO levels were significantly increased (P <0.05 or P < 0.01), and the ET-1 levels were significantly reduced (P <0.05 or P < 0.01).

Under the experimental conditions, after the SHR rat test sample is given for 30d, the blood pressure of Spontaneous Hypertension Rats (SHR) is obviously reduced in the group of the examples 1-4, the blood pressure reduction mechanism of the SHR rat test sample is related to the regulation of the levels of Ang II, NO and ET-1 in the serum of the SHR rat, and the blood pressure can be reduced by regulating the generation and release of Ang II, NO and ET-1 to regulate vascular endothelial functions and vasodilating blood vessels. The traditional Chinese medicine composition is obtained by comparing the examples 1-4 with the comparative examples 1-4, wherein the cinnamon extract, the eucommia bark extract and the pagodatree flower extract are compounded in the formula, the grape seed extract and the cocoa extract are compounded, and the use amount of each component is optimal compared with the effect when the use amount is within the protection range of the traditional Chinese medicine composition.

Finally, it should be noted that the above description is only for illustrating the technical solution of the present application, and not for limiting the scope of the present application, and that the simple modification and equivalent substitution of the technical solution of the present application can be made by those skilled in the art without departing from the spirit and scope of the technical solution of the present application.

Claims

1. The composition with the auxiliary blood pressure reducing function is characterized by comprising the following components in parts by weight: 3-5 parts of cinnamon extract, 10-20 parts of eucommia bark extract, 10-20 parts of pagodatree flower extract, 5-10 parts of grape seed extract and 25-30 parts of cocoa extract.

2. The composition according to claim 1, wherein the weight ratio of cinnamon extract, eucommia bark extract, pagodatree flower extract is 3-5:10-20:10-20.

3. The composition according to claim 2, wherein the weight ratio of cinnamon extract, eucommia bark extract, pagodatree flower extract is 4-5:12-18:12-18.

4. The composition according to claim 1, wherein the weight ratio of grape seed extract to cocoa extract is 5-10:25-30.

5. The composition of claim 4, wherein the weight ratio of grape seed extract to cocoa extract is 6-10:27-28.

6. Use of a composition according to any one of claims 1-5 for the preparation of a health food having an auxiliary blood pressure lowering function.

7. The use according to claim 6, wherein the formulation of the health food is any one of a tablet, a capsule, and a powder.